大行評級|花旗:重申平安好醫生爲醫療健康行業首選之一,目標價12港元
花旗重申平安好醫生爲其醫療健康行業首推企業之一,予其12港元的目標價。
研報指,平安健康於6月10日在上海舉辦品牌煥新發佈會,宣佈更名爲“平安好醫生”,並重磅發佈醫健服務。此次發佈會重點關注自有AI垂域模型與醫療服務場景的融合落地,通過“安主任”、“平安芯醫”等AI產品賦能,爲不同用戶、場景提供更全面優質的服務。
該行認爲,此次品牌重塑活動表明平安好醫生專注於提升C端用戶體驗,並堅定地實施其F2C和B2C戰略。該行看好平安好醫生自主研發的人工智能技術、強勁的財務表現以及堅定的業務戰略,將其列爲首選股票之一。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.